This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D76.3 | Synonyms: Rosai-Dorfman disease (RDD), SHML
Sinus histiocytosis with massive lymphadenopathy, that is, Rosai-Dorfman disease (RDD), was established as an independent clinicopathological entity in 1969 when Juan Rosai and Ronald Dorfman first described 4 patients. They named the disease after reporting massive enlargement of cervical lymph nodes, proliferation of large histiocytes within the lymph node sinuses, and the characteristic finding of lymphophagocytosis (emperipolesis).
Similar lesions had been reported individually even before the description by Rosai and Dorfman, but had not been classified as an independent disease. In 1972, Rosai and Dorfman analyzed more cases and formally proposed the name SHML. Subsequently, as reports of extranodal lesions and various clinical subtypes accumulated, the clinical spectrum of RDD broadened.
In the 2016 Histiocyte Society's new classification of histiocytic disorders, RDD was included in the 'R group'. Since 2016, somatic mutations of the MAPK pathway such as KRAS, NRAS, MAP2K1, ARAF have been found in some RDD cases, suggesting that RDD is not a purely reactive disease and may have clonal proliferative characteristics in part.
The exact cause of RDD has not yet been fully elucidated. It was traditionally classified as a reactive histiocytic proliferative disorder, but with the recent discovery of MAPK pathway mutations, a clonal mechanism is also understood to be involved in some cases.
Viral infections such as EBV, HHV-6, and parvovirus B19 have been proposed as triggers of RDD. However, a causal relationship with these viruses has not been fully established. Onset after bacterial infection has been reported in some cases.
RDD has been reported to coexist with autoimmune diseases such as autoimmune hemolytic anemia, SLE, and rheumatoid arthritis. Dysregulation of immune regulation is presumed to contribute to onset. Overlap with or differentiation from IgG4-related disease is also needed in some cases.
In some RDD cases, somatic mutations of the MAPK signaling pathway such as KRAS, NRAS (RAS proto-oncogenes), MAP2K1 (MEK1), ARAF are found. These mutations suggest that part of RDD is clonal proliferation rather than purely reactive, and open the possibility of applying targeted therapy such as BRAF inhibitors.
RDD rarely occurs in families, and no clear genetic predisposition has been established. It occurs sporadically as a rule.
In some RDD cases, histological findings and serological characteristics similar to IgG4-related disease (IgG4-RD) are observed. A genetic link between the two diseases has not been clearly established to date.
RDD is a rare disease, with only a few thousand cases reported worldwide. The exact incidence is unknown, but the number of cases occurring worldwide each year is estimated to be very small.
RDD can occur at any age but is frequent mainly in children, adolescents, and young adults aged 20 or younger. Onset within the first decade is not uncommon. Some reports indicate a slight male predominance.
In Korea, RDD is reported very rarely, with sporadic case reports in domestic pathology and hematology-oncology journals. It is often first discovered with cervical lymph node enlargement as the main symptom and is confirmed by tissue biopsy.
The core pathophysiology of RDD is abnormal proliferation and infiltration of S100-positive large histiocytes within the lymph node sinuses and various tissues. These histiocytes are called RDD histiocytes (Rosai-Dorfman histiocytes) and are characterized by emperipolesis, in which intact lymphocytes, plasma cells, red blood cells, and the like are contained within the cytoplasm.
Emperipolesis is a phenomenon in which another intact living cell (a lymphocyte, etc.) passes through or lies within the cytoplasm of one living cell (the engulfing histiocyte), and is distinguished from ordinary phagocytosis. Emperipolesis is a key feature in the pathological diagnosis of RDD.
Activating mutations of the MAPK pathway such as KRAS and MAP2K1 have been found in some RDD, and histiocyte proliferation due to overactivation of ERK signaling has been proposed as the mechanism. This suggests the possible use of BRAF/MEK inhibitors as therapeutic targets in RDD.
The most characteristic symptom of RDD is massive cervical lymphadenopathy. Bilateral, painless cervical lymph node enlargement is typical, and the nodes can grow from several cm to several tens of cm.
Fever, night sweats, weight loss, fatigue, and general malaise may accompany but do not always appear.
Extranodal lesions occur in about 25–40% of RDD. Symptoms by main site of involvement: Skin (the most common extranodal lesion): painless papules, nodules, and plaques. Central nervous system: headache, seizures, neurological deficits (with intracranial involvement). Paranasal sinuses/upper airway: nasal obstruction, epistaxis, visual disturbance (with orbital involvement). Bone, kidney, liver, spleen, testis, and thyroid may be involved.
Cervical (bilateral), axillary, and inguinal lymph node enlargement are the main physical findings. The nodes are characteristically elastic, mobile, and painless. Splenomegaly and hepatomegaly are observed in some patients.
Leukocytosis (neutrophilia), normocytic normochromic anemia, elevated ESR and CRP. Elevated serum immunoglobulins (polyclonal hypergammaglobulinemia). Findings of autoimmune hemolytic anemia (positive direct Coombs test, elevated bilirubin, elevated LDH): observed in some patients.
The pathological histological findings of a lymph node biopsy are the key to diagnosis.
| Findings | Features |
|---|---|
| Cytological features | Large histiocytes (RDD histiocytes) infiltrate the lymph node sinuses extensively |
| Emperipolesis | Intact lymphocytes, plasma cells, and red blood cells contained within the histiocyte cytoplasm |
| Background tissue | Fibrosis and plasma cell infiltration |
| Immunohistochemistry | S100+ strongly positive, CD68+, CD163+, CD1a-, langerin- |
Include RDD in the differential diagnosis when there is painless massive cervical lymph node enlargement progressing over weeks to months in children and young adults. Suspicion is higher especially when fever, night sweats, and polyclonal hypergammaglobulinemia accompany.
Complete blood count, ESR, CRP, and serum protein electrophoresis (SPEP) to check for hypergammaglobulinemia. Autoantibody tests (ANA, RF, anti-red blood cell antibodies) to evaluate coexisting autoimmune disease. LDH, uric acid, and beta-2 microglobulin tests to evaluate the possibility of lymphoma.
Cervical ultrasound is used for the initial assessment of the extent and characteristics of lymph node enlargement. CT or MRI is performed when extranodal involvement is suspected.
Definitive diagnosis of RDD is a pathological histological diagnosis by biopsy of the lymph node or involved tissue. Key findings: proliferation of large histiocytes within the lymph node sinuses and emperipolesis (lymphocytes contained within cells). Immunohistochemistry confirms strongly positive S100, positive CD68, negative CD1a, and negative langerin to differentiate from Langerhans cell histiocytosis.
In relapsed or treatment-refractory RDD, NGS panel testing for analysis of MAPK pathway mutations such as KRAS, MAP2K1, and ARAF helps in deciding targeted therapy.
Differentiation is needed from malignant lymphoma (Hodgkin lymphoma, non-Hodgkin lymphoma), Langerhans cell histiocytosis, reactive lymph node enlargement (EBV, CMV, etc.), tuberculous lymphadenitis, and IgG4-related disease.
Most RDD (especially the lymph node form) tends to undergo spontaneous remission over months to years, so observation is the preferred management in asymptomatic patients.
When symptomatic or when vital organs are involved, corticosteroids are used as first-line treatment. They are effective in reducing lesion size and relieving symptoms in some patients, but the effect on long-term remission is limited.
Surgical resection may be performed when vital structures are compressed or there are cosmetic problems. Surgical decompression may be needed especially in intracranial RDD or orbital involvement.
Cases have been reported in which immunosuppressants and chemotherapeutic agents such as methotrexate, 6-mercaptopurine, azathioprine, cladribine (2-CDA), and vinblastine were used for refractory RDD. When a MAPK pathway mutation is identified, targeted therapy with a BRAF inhibitor (vemurafenib) or MEK inhibitor (trametinib) is considered. Radiotherapy can be applied to locally refractory lesions.
The prognosis of RDD is generally good. Typical RDD of the lymph node form often resolves spontaneously after months to years, and it is rarely life-threatening.
Immunodeficiency (HIV infection, coexisting autoimmune disease), involvement of vital organs (kidney, liver, lung, central nervous system), coexisting malignancy such as lymphoma, and absence of response to treatment worsen the prognosis. Mortality is approximately 5–10%, mainly due to vital organ failure or coexisting malignancy.
In some patients, recurrence may occur after several years, and the frequency of recurrence is higher especially in the extranodal form.
The cause of RDD is unclear, so there is no specific prevention.
General hygiene measures are recommended to prevent viral infections reported to be associated with RDD, such as EBV and HHV-6. In immunosuppressed patients, prevention and monitoring of opportunistic viral infections such as EBV and CMV are performed.
In patients presenting with painless massive lymphadenopathy, perform early biopsy to exclude fatal diseases such as malignant lymphoma, and after RDD is confirmed, detect recurrence and complications early with regular imaging follow-up. Periodically assess the possibility of coexisting autoimmune disease or malignancy.